Scott Hoffman, MD
Cardiovascular Disease · Rochester, MNNPI 1316197809
Payments from drug & device makers
Across 80 payments — averaging $740.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$44K
- Philips North America LLC$11K
- Boston Scientific$4K
- Edwards Lifesciences$494
- W. L. Gore & Associates, Inc.$290
What the payments were for
- Consulting fees$57,04096%
- Travel & lodging$1,0512%
- Food & beverage$1,1432%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 46 | $43,838 |
| Philips North America LLC | 14 | $10,625 |
| Boston Scientific | 5 | $3,988 |
| Edwards Lifesciences | 14 | $494 |
| W. L. Gore & Associates, Inc. | 1 | $290 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VANTAGEVIEW$22,250
- NAVITOR$12,125
- (9520) IGT Devices Undivided$8,875
- XIENCE SKYPOINT$3,000
- JETi All In One Non-Sterile Kit$3,000
- GENERAL VASCULAR ACCESS$2,250
- WATCHMAN Access System$1,500
- Portico Transcatheter Aortic Heart Valve$1,375
- (9148) ICE 3D$1,000
- IGT Devices Und$750
- VantageView System$375
- Product in Development$290
- Epic$250
- OPTIS$204
- STINGRAY$149
- SAPIEN 3 Ultra RESILIA$133
How this compares
$59,235 in reported general payments places this provider in the 75th percentile of 451 cardiovascular disease providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 25 | $32,553 |
| XareltoRivaroxaban | 11 | $5,780 |
| Metoprolol Succinate | 64 | $953 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 28 | $529 |
| ClopidogrelClopidogrel Bisulfate | 35 | $513 |
| Lisinopril | 17 | $419 |
| Carvedilol | 19 | $372 |
| Atorvastatin Calcium | 23 | $358 |
| Torsemide | 11 | $317 |
| Spironolactone | 19 | $253 |
| Furosemide | 28 | $225 |
| Rosuvastatin Calcium | 12 | $208 |
| Amlodipine Besylate | 20 | $205 |
| Amoxicillin | 21 | $29 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Rochester
- Jae OhRochester$7.9M
- Yogesh ReddyRochester$7.9M
- Mayra GuerreroRochester$7.1M
- Martha GroganRochester$6.3M
- Mackram EleidRochester$3.5M
- David HolmesRochester$2.4M
- Mohamad Adnan AlkhouliRochester$2.1M
- Srijoy MahapatraRochester$2M
- Jeffrey GeskeRochester$1.9M
- Charanjit RihalRochester$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.